Trends in Women's Representation Among Principal Investigators in US Genetic Clinical Trials
Author Information
Author(s): Muacevic Alexander, Adler John R, Karimi Parmida, Abolghasemi Fard Asal, Parnia Aran, Kamvar Radin, Zojaji Seyedehhasti, Behroozi Narges, Karimi Amir
Hypothesis
What proportion of genetic clinical trial PIs are women, and how has this changed over time?
Conclusion
Women remain underrepresented as PIs in genetic clinical trials, with no sustained growth over time.
Supporting Evidence
- Women PIs conducted a higher number of behavioral and other interventions compared to men.
- Women received more federal funding than men in the trials analyzed.
- Men dominated industry funding in genetic clinical trials.
Takeaway
This study looked at how many women lead genetic clinical trials in the US and found that their numbers haven't really changed much over the years.
Methodology
Analyzed 4,112 genetic clinical trials registered on ClinicalTrials.gov from 2007 to 2024 using statistical analyses including Fisher's exact tests and univariate linear regression.
Potential Biases
Potential misclassification of gender due to ambiguous or culturally diverse names.
Limitations
The study relied on ClinicalTrials.gov data, which may not include all trials, and used Genderize.io for gender classification, which may misclassify names.
Participant Demographics
Women comprised 37.7% of PIs in the analyzed trials.
Statistical Information
P-Value
0.35
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website